All In Biotech

Drug Trial Radar · NCT05806359

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants

A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Danicamtiv in Healthy Japanese and Caucasian Participants

Last checked: Nov 20, 2026Latest source record: May 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

33

Actual

Start

Mar 31, 2023

Primary completion

Aug 14, 2023

Study completion Aug 14, 2023

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Apr 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, and single-dose pharmacokinetics of danicamtiv in healthy Japanese and Caucasian participants.

Conditions

  • Healthy Volunteers

Interventions

  • DanicamtivDrug

    Specified dose on specified days

  • PlaceboDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs)Time frame: Day 1 up to Day 28
  2. Number of Participants with Vital Sign AbnormalitiesTime frame: Day 1 up to Day 7
  3. Number of Participants with Electrocardiogram (ECG) AbnormalitiesTime frame: Day 1 up to Day 7
  4. Number of Participants with Physical Examination AbnormalitiesTime frame: Day 1 up to Day 7
  5. Number of Participants with Clinical Laboratory AbnormalitiesTime frame: Day 1 up to Day 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Anaheim Clinical Trials

    Anaheim, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.